Buy & Sell Synopsys, Inc. (SNPS) – Synopsys, Inc. Price Today
Aura AI Summary
Key Stats
- $96.54BMarket Cap
- TechnologySector
- -15.17%3M Drawdown
- $105.21BEnterprise Value
- -Dividend Yield
- 100% Buy | 0% SellTrading Activity
- 77 daysTypical Hold Time
Synopsys, Inc. (SNPS) is currently valued at a market capitalization of $96.54B, with an enterprise value of $105.21B. Over the past 52 weeks, Synopsys, Inc. has traded between a low of $380.47 and a high of $645.59, highlighting its annual price range. Over the past three months, Synopsys, Inc. has recorded a drawdown of -15.17%, reflecting recent price volatility. On average, investors hold Synopsys, Inc. for approximately 77 days, indicating typical investor behavior on the platform.
About Synopsys, Inc.
Synopsys is a provider of electronic design automation software, intellectual property, and software integrity products. EDA software automates the chip design process, enhancing design accuracy, productivity, and complexity in a full-flow end-to-end solution. The firm's growing SI business allows customers to continuously manage and test the code base for security and quality. Synopsys' comprehensive portfolio is benefiting from a mutual convergence of semiconductor companies moving up-stack toward systems-like companies, and systems companies moving down-stack toward in-house chip design. The resulting expansion in EDA customers alongside secular digitalization of various end markets benefits EDA vendors like Synopsys.
Most Recent News
CN Energy's Pathenbot launches intelligent robotic cargo sorting in the US with a 100,000-unit order.
CN Energy Group's subsidiary Pathenbot has signed an order to provide intelligent robotic cargo sorting services in the United States, marking the commercial launch of these services. The initial order covers 100,000 units and includes barcode scanni...
BioNTech to present promising late-stage cancer drug data at 2026 ASCO meeting
BioNTech will showcase new clinical data for its late-stage oncology drugs pumitamig and gotistobart at the 2026 ASCO Annual Meeting. Pumitamig showed encouraging anti-tumor activity in first-line non-small cell lung cancer, while gotistobart demonst...
BioNTech reveals promising late-stage cancer drug data at ASCO 2026, advancing treatments for lung and ovarian cancers.
BioNTech presented encouraging clinical data for its late-stage cancer drug candidates Pumitamig and Gotistobart at the ASCO 2026 meeting. Pumitamig showed promising anti-tumor activity in a Phase 2/3 study for first-line treatment of non-small cell ...